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Abstract
Background: Uncontrolled hypertension is a major cardiovascular risk factor. We examined uncontrolled
hypertension and differences in treatment regimens between a high-risk country, Russia, and low-risk Norway to
gain better understanding of the underlying factors.
Methods: Population-based survey data on 40–69 year olds with hypertension defined as taking antihypertensives
and/or having high blood pressure (140+/90+ mmHg) were obtained from Know Your Heart Study (KYH, N = 2284),
Russian Federation (2015–2018) and seventh wave of The Tromsø Study (Tromsø 7, N = 5939), Norway (2015–2016).
Uncontrolled hypertension was studied in the subset taking antihypertensives (KYH: N = 1584; Tromsø 7: 2792)and
defined as having high blood pressure (140+/90+ mmHg). Apparent treatment resistant hypertension (aTRH) was
defined as individuals with uncontrolled hypertension on 3+ OR controlled on 4+ antihypertensive classes in the
same subset.
Results: Among all those with hypertension regardless of treatment status, control of blood pressure was achieved
in 22% of men (KYH and Tromsø 7), while among women it was 33% in Tromsø 7 and 43% in KYH. When the
analysis was limited to those on treatment for hypertension, the percentage uncontrolled was higher in KYH (47.8%,
CI 95 44.6–50.9%) than Tromsø 7 (38.2, 36.1–40.5%). The corresponding figures for aTRH were 9.8% (8.2–11.7%) and
5.7% (4.8–6.8%).
Antihypertensive monotherapies were more common than combinations and used by 58% in Tromsø 7 and 44% in
KYH. In both KYH and Tromsø 7, untreated hypertension was higher in men, those with no GP visit in the past year
and problem drinkers. In both studies, aTRH was associated with older age, CVD history, obesity, and diabetes. In
Tromsø 7, also male gender and any drinking. In KYH, also chronic kidney disease.
Conclusion: There is considerable scope for promoting combination therapies in line with European treatment
guidelines in both study populations. The factors associated with untreated hypertension overlap with known
correlates of treatment non-adherence and health check non-attendance. In contrast, aTRH was characterised by
obesity and underlying comorbidities potentially complicating treatment.
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Background
Mortality from cardiovascular disease (CVD) has been
falling rapidly in Russia since 2005 [1]. This is thought
to be due, in part, to better detection, treatment, and
control of hypertension [2–4]. Yet, despite this impres-
sive progress, control of blood pressure remains rela-
tively poor and there is a persisting mortality gap with
countries of Western Europe. At first sight, there is no
good reason for this. Russia has an extensive health sys-
tem with, in comparative terms, large numbers of health
workers [5]. Hypertension is easily diagnosed and can be
treated with a range of safe and effective medicines [6],
widely available in Russian pharmacies [7].
An effective response is clearly needed but this must
be informed by a detailed understanding of why Russia
has been unable to achieve better control of blood pres-
sure. This study seeks to inform such a response by
examining in detail the characteristics of a population
sample of Russians, who have been initiated on antihy-
pertensive treatment but whose blood pressure remains
uncontrolled. It compares them with similarly defined
individuals from neighbouring Norway to assess whether
there are lessons that can be learnt from its compara-
tively better control of blood pressure.
In the study we compare uncontrolled and apparent
treatment resistant hypertension among those taking anti-
hypertensives in population-based samples from Russia and
Norway as well as the proportion of individuals achieving
blood pressure control among all with hypertension.
Methods
Data selection criteria
Know Your Heart (KYH) is a cross-sectional, population-
based study of cardiovascular structure, function, and risk
factors in over 4500 men and women aged 35–69 years
living in two Russian cities, Arkhangelsk and Novosibirsk,
2015–2018 [8]. The Tromsø Study is a longitudinal,
population-based, prospective study with repeated data
collections since 1974 in the municipality of Tromsø in
Northern Norway. Data from the seventh wave of the
study, Tromsø 7 (2015–2016), were used [9].
A total of 2284 and 5939 participants were selected for
this study from KYH and Tromsø 7, respectively, based
on the following inclusion criteria: aged 40–69 years,
non-missing systolic and diastolic blood pressure meas-
urement, measured hypertension (systolic pressure of
140+ mmHg and/or a diastolic of 90+ mmHg) or taking
antihypertensives [6]. A subset of participants, those tak-
ing antihypertensives (1584 from KYH and 2792 from
Tromsø 7), were then selected to study uncontrolled and
apparent treatment resistant hypertension. A flow dia-
gram of the sample selection is presented in Figure S1
(Supplementary materials). Response rates for the health
check component in KYH was 67% in Arkhangelsk and
37% in Novosibirsk [8] (denominator: all issued, exclud-
ing addresses not found or where no one of target age
and gender were found). The response rate in Tromsø 7
was 65% [9].
Blood pressure measurement
In KYH, blood pressure was measured using OMRON
705 IT blood pressure monitors (OMRON Healthcare,
Kyoto, Japan). All devices were calibrated before and
after the fieldwork period and no adjustments were
needed. Blood pressure in the Tromsø 7 study was mea-
sured using Dinamap ProCare 300 blood pressure moni-
tors (GE Healthcare, Oslo, Norway) calibrated before the
fieldwork. In both studies three measurements were
taken with two minutes seated rest in between [8]. Par-
ticipants were assigned to different antihypertensive clas-
ses based on their systolic and diastolic blood pressure
(average of last two out of three measurements) accord-
ing to the European hypertension treatment guidelines
[6] and antihypertensive use.
Medication
Participants in both Know Your Heart (KYH, Russian
Federation) and Tromsø 7 (Norway) were asked ques-
tions about their use of antihypertensives, although the
protocols differed in some minor respects. In KYH, a
baseline interview was administered by a trained non-
medical interviewer. Participants who reported ever be-
ing diagnosed with hypertension were asked a series of
questions about prescription and use of blood pressure
medication. At the end of the interview all participants
were invited to attend a health check to which they were
asked to bring all their medications. At the health check,
a trained medical interviewer asked the participant about
current medication use and recorded the name, dose, in-
dication and frequency of use of medications (up to 7
medications). About a third (33%) of KYH participants
brought their medicines with them to the health assess-
ment and for the remaining two thirds (67%), the record
taking was verbatim. In Tromsø 7, all participants were
asked about current or previous use of antihypertensive
medications. Furthermore, participants were asked to
state the name of all medications (prescription and non-
prescription drugs) they had used regularly during the
last four weeks (up to 20 medications). The question-
naire was checked by a trained technician at the study
site, and participants had to confirm if no medication
use was reported. For both studies listed medications
were coded using the International WHO Anatomical
Therapeutic Chemical (ATC) classification system [10].
Antihypertensive medication was defined as medications
within the following ATC classes: Antihypertensives (ab-
breviation: AH; ATC code: C02), Diuretics (DIU; C03),
Beta blockers (BB; C07), Calcium channel blockers
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(CCB; C08), ACE inhibitors (ACE; C09A/B), Angiotensin
II receptor blockers (ARB; C09C/D).
The main analyses were based on ATC coding of re-
ported medications. Sensitivity analyses were conducted
using self-reported positive response to an explicit ques-
tion about whether the participant regularly took antihy-
pertensive medication.
Outcome
Uncontrolled hypertension was studied in those on anti-
hypertensive medication in two different ways. First, as
uncontrolled hypertension in the usual sense, i.e. individ-
uals on antihypertensives and with systolic blood pressure
140+ mmHg and/or a diastolic of 90+ mmHg. Second, as
apparent treatment resistant hypertension (aTRH), i.e. in-
dividuals with uncontrolled hypertension on 3+ OR con-
trolled on 4+ antihypertensive classes [11]. In a clinical
setting, a patient would only be diagnosed with treatment
resistant hypertension following a medication review, an
assessment of medication adherence, and a series of ele-
vated out-of-office blood pressure measurements. All of
these factors are rarely present in large epidemiological
studies and aTRH has shown to provide useful insights in
various studies including NHANES studies [11, 12].
The prevalence of uncontrolled hypertension and
aTRH among those with treated hypertension was esti-
mated and standardised by age and sex to the 2013
European Standard Population [13].
Co-variates
A range of co-variates was included to study factors asso-
ciated with hypertension, CVD risk, CVD prevention, and
healthcare system use, i.e. gender, age, education, whether
living with a partner, body mass index, alcohol use, CVD
history, and primary healthcare visits. The equivalent co-
variates from KYH and Tromsø 7 were harmonised in
terms of coding frames and standard classifications.
Chronic kidney disease (CKD) status was defined as
Glomerular Filtration Rate (eGFR) below 60ml/min/
1.73m2 based on serum creatinine [14].
Self-reported alcohol-related behaviours were cate-
gorised as: non-drinker past year versus low risk drinkers
(score < 8) versus high risk drinkers (score 8+) according
to WHO Alcohol Use Disorders Identification Test
(AUDIT) [15].
For KYH, the responses to a question on household fi-
nancial constraints were classed into the following cat-
egories: perceived to be constrained in buying food or
clothes, able to buy food or clothes but constrained in
buying large domestic appliances, able to buy both. No
equivalent variable was available from Tromsø 7.
The presence of diabetes was ascertained on either
self-reported diabetes or taking diabetes medication
(ATC A10: insulin or oral antidiabetics) or HbA1c 48+
mmol/mol (> 6.5%) [16].
Serum total cholesterol (mmol/L) was combined with
data on age, sex, smoking status, and systolic blood pres-
sure to calculate 10-year risk of a fatal CVD event ac-
cording to the SCORE tool equations for high risk
countries and divided into three risk groups for the de-
scriptive analyses: Low (< 1%), Moderate (1–4.9%), High
(5 + %) [17] (pers.comm. Dr. T. Fitzgerald for additional
information regarding the Conroy et al. (2003) risk equa-
tions in line with the European Cardiology Society’s on-
line CVD risk calculator).
A history of CVD was defined as self-report of one or
more of the following conditions: myocardial infarction,
heart failure, atrial fibrillation, angina, stroke.
Whether the participant had visited a primary care
consultant in the past year was also included (KYH: gen-
eral practice or polyclinic; Tromsø 7: general practice).
Biomarker data from KYH (total cholesterol, HbA1c,
serum creatinine) were corrected for inter-laboratory
variation (Iakunchykova O, Averina M, Wilsgaard T,
Leon DA: Recalibration of Blood Analytes in Know Your
Heart Study for Comparisons with Tromsø 7 study - Im-
pact of Recalibration on Mean Levels and Prevalence es-
timates, in preparation).
Regression analyses
Multivariate logistic regression models of uncontrolled
versus controlled hypertension and aTRH versus non-
aTRH in 40–69 year olds with treated hypertension were
fitted adjusting for gender and age, or gender, age, and
CVD history while including the following covariates:
study, education, body mass index, smoking, alcohol
consumption, diabetes, CKD, and primary healthcare
visits. Statistical analyses were carried out using Stata 15
[18]. CVD history was included in the adjusted analyses
together with gender and age due to the well-known dif-
ferences in CVD burden between the two countries and
the higher propensity for being and staying on antihy-
pertensives for this group [19]. Potential interactions be-
tween age group, gender, age group, and CVD history
for the two outcomes were tested with likelihood ratio
tests in a restricted versus unrestricted model scenario.
Results
A total of 1584 and 2792 40–69 year olds were on antihy-
pertensives in KYH and Tromsø 7, respectively (for the
characteristics of study participants, see Table 1). Individ-
uals in Russia were more likely to have uncontrolled
hypertension, at 55.7% (95% CI 50.6–60.6) in males and
42.7% (38.9–46.7) in females than in Norway (Table 2),
where the corresponding percentages were 43.6% (40.4–
46.8) and 33.0% (30.2–35.9). The proportion of people
with hypertension who had aTRH was also higher in
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Table 1 Characteristics of participants by study (age- and sex-standardised to 2013 European Standard Population)
Characteristic Level KYH Tromsø 7
N % N %
Study total Total 1584 100 2792 100
Age group 40–44 yr 80 5.1 151 5.4
45–49 yr 125 7.9 273 9.8
50–54 yr 198 12.5 334 12.0
55–59 yr 296 18.7 502 18.0
60–64 yr 405 25.6 720 25.8
65–69 yr 480 30.3 812 29.1
Gender Male 598 38.0 1454 50.8
Female 986 62.0 1338 49.2
Education Elementary 245 12.9 744 21.7
Lower intermediate 204 12.1 891 33.5
Higher intermediate 652 42.4 524 20.5
Graduate 483 32.5 611 24.4
Economic activity Paid work 248 34.5 1668 71.5
Looking after home 152 7.1 16 0.4
Unemployed 24 2.8 15 0.7
Retired 1145 53.9 551 10.0
Other 15 1.6 504 17.3
Financial constraints Constrained 365 22.0 N/A N/A
Intermediary 800 50.2 N/A N/A
Rel. unconstrained 398 27.8 N/A N/A
Single No 1039 67.4 2064 77.8
Yes 545 32.6 595 22.2
Smoking No 1262 74.4 2394 87.0
Yes 320 25.6 356 13.0
Alcohol use disorder Non-drinker past year 1145 67.6 1398 52.3
Low (AUDIT< 8) 284 20.8 865 33.9
High (AUDIT 8+) 150 11.5 322 13.8
Body Mass Index Under/Normal (< 25) 226 15.7 498 17.3
Overweight (25–29) 572 34.3 1167 39.0
Obese (30–34) 489 29.8 765 28.5
Very obese (35+) 293 20.1 344 15.2
Diabetic No 1182 79.7 2366 84.9
Yes 402 20.3 426 15.1
SCORE 10-year CVD risk% Low (< 1%) 232 33.8 466 34.7
Intermediate (1–4.9%) 755 44.5 1325 45.6
High (5 + %) 564 21.7 949 19.7
Seen GP past year No 301 19.1 192 7.1
Yes 1283 80.9 2589 92.9
CKD No 1516 96.7 2694 97.2
Yes 68 3.3 98 2.8
CVD history No 910 65.9 2100 79.5
Yes 674 34.1 692 20.5
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Russia, at 10.8% (8.1–14.1) in males and 9.2% (7.3–11.6)
in females (Table 2). The corresponding shares in Tromsø
7 were 6.9% (5.4–8.7) and 4.5% (3.4–5.9). Controlling for
age, gender, and CVD history, these gaps persisted, with
adjusted odds ratios (AOR: KYH/Tromsø 7) of 1.65 (95%
CI 1.45–1.87) for uncontrolled hypertension and 1.58
(1.26–1.98) for aTRH (Table 2). The gaps also persisted
when controlling for a wider range of co-variates (Table
2). The sensitivity analyses based on participants’ response
to a question about taking antihypertensives rather than
the ATC-coding of self-reported medication used in the
main analyses yielded similar results (Table 2).
For KYH, the proportions with controlled hyperten-
sion (defined as blood pressures < 140/< 90 mmHg and
taking antihypertensives) out of all those with hyperten-
sion were 22.2% (19.6–25.1) for males and 43.0% (39.7–
46.3) for females. For Tromsø 7, the equivalent figures
were similar for males at 22.4% (21.0–23.8), but lower
for females, 32.6% (30.6–34.8).
The frequency of antihypertensive use by drug class and
whether hypertension was controlled or not showed that
monotherapies were used in Tromsø 7 by as many as 58%
of participants, whereas in KYH the same proportion was
only 44%. While there was a declining number of partici-
pants for each additional drug class used, KYH had a
Table 2 Prevalence of uncontrolled and an apparent treatment resistant hypertension (aTRH) and odds ratios (AOR; 95% CI) for
inter-study effects









Uncontrolled hypertension Male 55.7 (50.6 to 60.6) 43.6 (40.4 to 46.8) 1.90 (1.56;2.30) 2.03 (1.67;2.47) 1.97 (1.59;2.44)
Female 42.7 (38.9 to 46.7) 33.0 (30.2 to 35.9) 1.30 (1.10;1.54) 1.35 (1.14;1.61) 1.22 (1.01;1.49)
Total 47.8 (44.6 to 50.9) 38.2 (36.1 to 40.5) 1.54 (1.36;1.75) 1.65 (1.45;1.87) 1.59 (1.39;1.83)
Totala 48.7 (45.2 to 52.2) 41.7 (39.5 to 44.0) N/A N/A N/A
aTRH Male 10.8 (8.1 to 14.1) 6.9 (5.4 to 8.7) 1.62 (1.18;2.21) 1.50 (1.09;2.06) 1.58 (1.12;2.24)
Female 9.2 (7.3 to 11.6) 4.5 (3.4 to 5.9) 2.05 (1.50;2.80) 1.61 (1.16;2.23) 1.43 (0.98;2.08)
Total 9.8 (8.2 to 11.7) 5.7 (4.8 to 6.8) 1.83 (1.47;2.28) 1.58 (1.26;1.98) 1.49 (1.16;1.91)
Totala 10.2 (8.4 to 12.3) 5.5 (4.5 to 6.6) N/A N/A N/A
a) Sensitivity analysis based on self-reported antihypertensive use where the main analyses were based on ATC coding of participant medication. b) Age, sex, CVD
history, smoking, AUDIT, BMI, Diabetes, Seen GP past year, CKD
Fig. 1 Number of antihypertensive drug classes used by study and whether hypertension was controlled or not
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longer right-hand tail, i.e. synonymous with greater use of
multiple therapies than in Tromsø 7 (Fig. 1).
ACE inhibitors, ARB, and BB were widely used as
monotherapies in both studies; ARB (24.2% of all with
treated hypertension) was the most commonly used
therapy in Tromsø 7, while ACE (15.5%) was the most
common in KYH (Fig. 2). In KYH, diuretics was used by
3.2% on its own and 22.5% were at least treated with a
diuretic. In Tromsø 7, the same proportions were 5.2
and 13.1%. A total of 43 participants (2.7%) in KYH and
14 (0.5%) in Tromsø 7 were treated with ACE and ARB
concomitantly. No significant associations were found
between uncontrolled hypertension status and being
treated with either a monotherapy or combination ther-
apy (Table S1).
Multivariate logistic regression models showed the fol-
lowing factors to be associated with uncontrolled hyper-
tension among those treated for hypertension in both
countries: older age, male gender, alcohol use disorder
(AUDIT 8+), and not seeing a primary care doctor in
the past year (Table 3). Additionally, the absence of
CVD history was associated with uncontrolled hyperten-
sion in Tromsø 7. No significant interactions were found
between gender and age group or age group and CVD
history for the two outcomes in either study.
In KYH, aTRH was associated with older age, CVD
history, severe obesity (BMI 35+), diabetes, and CKD
(Table 4). In Tromsø 7, aTRH was associated with older
age, male gender, CVD history, any drinking, obesity
(BMI 30–34) and severe obesity, and diabetes.
Discussion
The prevalence of hypertension was found to be very
high in the Russian population-based study, Know Your
Heart (KYH), and this is consistent with other data from
Russia [2, 3, 20]. Among those taking antihypertensives
in both KYH and Tromsø 7, there were high proportions
of individuals with uncontrolled hypertension; although
higher in the Russian study (47.8%), compared to the
Norwegian study (38.2%). The findings for KYH are con-
sistent with a concurrent cross-sectional study of 25–64
year olds in four other regions of Russia, ESSE-RF-2
Study [3]. This study found that 50.3% of those treated
for hypertension were uncontrolled.
Among all those with hypertension, blood pressure
control was achieved in 22% of men (KYH and Tromsø
7), while among women it was 33% in Tromsø 7 and
43% in KYH. The concurrent Russian ESSE-RF-2 Study
found lower levels of hypertension control but similar to
those in KYH, i.e. 16.5% in males and 34.1% in females
[3]. In comparison, a study with data from 123 nationally
representative surveys of 40–79 year olds in 12 high in-
come countries [21] found that control in males ranged
from 17% in Ireland to 69% in Canada. For females,
from 26% in Ireland to 58% in Germany. Both KYH and
Tromsø 7 would, in other words, be at the bottom of
Fig. 2 Antihypertensive use by drug class and study. AH = Antihypertensives (ATC code: C02), DIU = Diuretics (C03), BB=Beta blockers (C07), CCB=
Calcium channel blockers (C08), ACE = ACE inhibitors (C09A/B), ARB = Angiotensin II receptor blockers (C09C/D)
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the range, except that females in KYH would be in the
middle of this range.
Monotherapies were widely used in both countries,
58% in Tromsø 7 and 44% in KYH. This is contrary to
the current European treatment guidelines, which rec-
ommend a diuretic to be combined with a drug acting
on the renin system (ACE or ARB) or that at least two
different drug classes are to be combined [6]. For com-
parison, the prevalence for monotherapy use in the US
(2009–2014) was only 37% [12].
Those with uncontrolled hypertension were less likely
to have visited a primary care doctor in the past year than
those with controlled hypertension. Poor adherence to an-
tihypertensive therapies may also play a role in the levels
of uncontrolled hypertension observed in both studies.
Many of the factors found to be associated with uncon-
trolled hypertension overlap with known factors for poor
drug adherence [19, 22] and health check non-attendance
[23], i.e. male gender, no primary care visit in the past
year, problem drinking, and absence of CVD history. Simi-
larly, poor adherence to lifestyle changes in terms of e.g.
weight loss, exercise, dietary salt reduction, etc. could
compound the effectiveness of hypertension control for
individuals. A recent review of Russian hypertension
Table 3 Logistic regression models of uncontrolled versus controlled hypertension in: Know Your Heart (KYH, Russia, N = 1584)
relative to Tromsø 7 (T7, Norway, N = 2792)
Characteristic Level KYH Russia T7 Norway
AOR gender/age AOR gender/age/CVD AOR gender/age AOR gender/age/CVD
Age group 40–49 yr Ref Ref
50–59 yr 1.25 (0.90;1.74) 1.13 (0.88;1.44)
60–69 yr 1.45 (1.07;1.98) 1.53 (1.22;1.91)
Gender Female Ref Ref
Male 1.82 (1.48;2.24) 1.25 (1.08;1.46)
CVD history No Ref Ref
Yes 0.83 (0.67;1.02) 0.65 (0.54;0.78)
Education Elementary Ref Ref Ref Ref
Lower intermediate 0.97 (0.67;1.42) 0.97 (0.67;1.43) 0.92 (0.75;1.12) 0.91 (0.74;1.11)
Higher intermediate 0.79 (0.58;1.07) 0.79 (0.58;1.07) 0.96 (0.75;1.21) 0.96 (0.76;1.21)
Graduate 0.79 (0.58;1.08) 0.78 (0.57;1.07) 0.81 (0.65;1.02) 0.81 (0.64;1.00)
Financial constraints Constrained Ref Ref Ref Ref
Intermediary 0.97 (0.75;1.24) 0.95 (0.74;1.23) N/A N/A
Rel. unconstrained 0.96 (0.72;1.29) 0.94 (0.70;1.26) N/A N/A
Single No Ref Ref Ref Ref
Yes 0.95 (0.76;1.19) 0.96 (0.77;1.21) 1.06 (0.88;1.27) 1.07 (0.89;1.43)
Smoking No Ref Ref Ref Ref
Yes 0.92 (0.71;1.19) 0.92 (0.71;1.20) 0.81 (0.64;1.02) 0.83 (0.65;1.05)
Alcohol use disorder Non-drinker past year Ref Ref Ref Ref
Low (AUDIT< 8) 1.13 (0.85;1.79) 1.11 (0.84;1.47) 1.16 (0.97;1.39) 1.16 (0.97;1.39)
High (AUDIT 8+) 1.71 (1.15;2.54) 1.69 (1.13;2.51) 1.35 (1.04;1.74) 1.37 (1.06;1.78)
Body Mass Index Under/Normal (< 25) Ref Ref Ref Ref
Overweight (25–29) 1.32 (0.97;1.81) 1.32 (0.96;1.80) 1.03 (0.83;1.29) 1.03 (0.83;1.28)
Obese (30–34) 1.32 (0.96;1.82) 1.32 (0.96;1.82) 1.16 (0.92;1.47) 1.16 (0.92;1.47)
Very obese (35+) 1.19 (0.83;1.69) 1.19 (0.84;1.71) 1.28 (0.96;1.70) 1.26 (0.95;1.68)
Diabetic No Ref Ref Ref Ref
Yes 0.93 (0.74;1.18) 0.95 (0.75;1.19) 1.03 (0.83;1.27) 1.03 (0.83;1.27)
Seen GP past year No Ref Ref Ref Ref
Yes 0.58 (0.44;0.75) 0.59 (0.45;0.76) 0.67 (0.50;0.90) 0.67 (0.50;0.91)
CKD No Ref Ref Ref Ref
Yes 1.25 (0.76;2.08) 1.27 (0.77;2.08) 1.09 (0.73;1.65) 1.11 (0.74;1.68)
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research found evidence that lower education and single
status were associated with lower adherence but differ-
ences were not significant in this study [19], perhaps be-
cause of insufficient power to detect such a difference.
The prevalence of aTRH was 9.8% in KYH and 5.7% in
Tromsø 7. For comparison, the prevalences of aTRH were
14.5% in a US population-based study (2005–2008) [11]
and 6.4% in a UK primary care database study [24]. The
UK and US studies included those aged above 70 years
and may thus be inflated relative to the present study of
40–69 year olds.
The factors associated with aTRH were indicative of pa-
tient level factors, i.e. CVD history, obesity, and diabetes.
These associations are well-known in the literature, as
hypertension is harder to control in patients with obesity
and some co-morbidities [6, 11]. Patients with CKD are
also known to be at risk of circulatory system conditions
including aTRH [11]. The odds ratios for CKD was found
statistically significant in KYH, but not in Tromsø 7.
There were some differences in the factors associated
with aTRH between the two countries. The associations
with CVD history was stronger in Russia than in Norway.
This suggests that the Russian participants with aTRH
Table 4 Logistic regression models of aTRH versus non-aTRH in: Know Your Heart (KYH, Russia, N = 1584) relative to Tromsø 7 (T7,
Norway, N = 2792)
Characteristic Level KYH Russia T7 Norway
AOR gender/age AOR gender/age/CVD AOR gender/age AOR gender/age/CVD
Age group 40–49 yr Ref Ref
50–59 yr 1.00 (0.56;1.81) 1.52 (0.84;2.77)
60–69 yr 1.77 (1.04;3.02) 2.47 (1.43;4.27)
Gender Female Ref Ref
Male 1.12 (0.81;1.53) 1.41 (1.04;1.91)
CVD history No Ref Ref
Yes 2.42 (1.74;3.37) 1.78 (1.29;3.89)
Education Elementary Ref Ref Ref Ref
Lower intermediate 1.06 (0.59;1.89) 1.03 (0.57;1.85) 0.81 (0.54;1.21) 0.82 (0.55;1.22)
Higher intermediate 1.09 (0.69;1.74) 1.08 (0.68;1.72) 0.89 (0.57;1.41) 0.89 (0.57;1.41)
Graduate 0.97 (0.59;1.58) 1.03 (0.63;1.69) 1.17 (0.77;1.76) 1.18 (0.78;1.78)
Financial constraints Constrained Ref Ref Ref Ref
Intermediary 0.99 (0.67;1.47) 1.06 (0.71;1.58) N/A N/A
Rel. unconstrained 1.11 (0.71;1.75) 1.29 (0.82;2.05) N/A N/A
Single No Ref Ref Ref Ref
Yes 0.80 (0.56;1.15) 0.77 (0.53;1.11) 1.17 (0.82;1.67) 1.15 (0.80;1.65)
Smoking No Ref Ref Ref Ref
Yes 0.69 (0.43;1.06) 0.68 (0.43;1.06) 0.77 (0.46;1.27) 0.73 (0.44;1.22)
Alcohol use disorder Non-drinker past year Ref Ref Ref Ref
Low (AUDIT< 8) 0.93 (0.59;1.46) 1.02 (0.64;1.60) 1.44 (1.01;2.05) 1.45 (1.02;2.07)
High (AUDIT 8+) 1.00 (0.55;1.81) 1.10 (0.60;2.02) 1.65 (1.03;2.65) 1.63 (1.01;2.63)
Body Mass Index Under/Normal (< 25) Ref Ref Ref Ref
Overweight (25–29) 1.28 (0.71;2.30) 1.32 (0.73;2.37) 1.28 (0.76;2.14) 1.28 (0.76;2.16)
Obese (30–34) 1.73 (0.97;3.10) 1.75 (0.97;3.15) 1.94 (1.15;3.29) 1.95 (1.15;3.31)
Very obese (35+) 3.15 (1.73;5.73) 3.10 (1.70;5.68) 3.84 (2.19;6.72) 3.97 (2.27;6.97)
Diabetic No Ref Ref Ref Ref
Yes 2.40 (1.74;3.32) 2.31 (1.67;3.26) 2.31 (1.64;3.24) 2.32 (1.65;3.27)
Seen GP past year No Ref Ref Ref Ref
Yes 1.26 (0.82;1.92) 1.14 (0.74;1.75) 1.43 (0.74;2.75) 1.42 (0.73;2.74)
CKD No Ref Ref Ref Ref
Yes 2.29 (1.27;4.13) 2.20 (1.21;4.00) 1.56 (0.81;3.00) 1.52 (0.79;2.93)
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had higher levels of comorbidity. There was only an asso-
ciation of aTRH with alcohol use disorder in Norway. One
possible explanation for this difference could be a higher
proportion of ‘sick quitters’ in the Russian study popula-
tion, i.e. individuals who stop a health harming behaviour
upon diagnosis with a related health condition.
Interventions to improve hypertension control con-
front different challenges and opportunities in these two
countries. Russia has a general health check programme
[5], while Norway does not. In Norway antihypertensive
medicines are only available on prescription, whereas in
Russia it is possible to obtain any marketable antihyper-
tensive from a pharmacy over-the-counter (OTC). A
drug may thus be taken either because it was prescribed
or the patient chose, perhaps on the recommendation of
a pharmacist, to purchase it [7]. Moreover, patients with
hypertension in Norway are reimbursed most of the pre-
scriptions costs [25], while only certain groups including
war veterans and recipients of the minimum state pen-
sion are reimbursed in Russia [7].
Pharmacists play a particularly important role in the
Russian health system, something only a few studies have
to date looked at, such as the quality of advice given to pa-
tients and opportunities for follow-up.
Antihypertensive combinations that included both ACE
inhibitors and ARB were used in both study populations
contrary to European treatment guidelines [6]. These two
agents both act through the renin-angiotensin system and
as a combination not as effective as if patients are treated
with drugs with complementary mechanisms. Patients
using this combination are also more likely to experience
adverse renal events including kidney failure [6]. In abso-
lute terms, this contraindicated co-prescription was rela-
tively rare; 2.7% in the Russian study and 0.5% in the
Norwegian one. Electronic prescribing, which includes
alerts to potential problems, is used in primary care and
pharmacies in Norway, which may explain why this com-
bination was rarer in Norway than Russia. Greater use of
multi-drug combinations could potentially reduce pre-
scription errors and improve adherence by reducing the
“pill burden” for patients [26], but typically reduces treat-
ment options in terms of dose, formulation, and more
individualised prescribing. A recent review of Russian an-
tihypertensive adherence studies however concluded that
patient education, telephone reminders, home blood pres-
sure monitoring, and fixed drug combinations were the
most important factors for improving adherence [19].
A range of lifestyle factors are associated with hyper-
tension and are assessed as part of standard medical ad-
vice, e.g. initiating weight loss, increasing exercise, and
reducing dietary salt intake [27, 28]. Adherence to life-
style change recommendations is thus another potential
avenue for future research [29].
Analysis of different therapies by aTRH status was lim-
ited in this study by the relatively small sample size and
should be replicated in a large database study to properly
assess the treatment regimens for this patient group.
Limitations
Sampling bias introduced by non-response in KYH was
assessed by comparing the realised sample against data
from the Russian Census 2010 on age, gender, and higher
education attainment [8]. Overall, the realised sample for
the health check was close to equity, ratio of 0.99 (95% CI
0.93–1.06) for Arkhangelsk and 1.26 (1.17–1.34) for
Novosibirsk.
Determination of uncontrolled hypertension and treat-
ment resistance in a survey differs from that in clinical
practice, where the treatment regimen, any side effects,
and adherence would be reviewed together, perhaps with
advice on other actions such as home blood pressure
monitoring. This is a limitation that should be borne in
mind when interpreting the findings from this and simi-
lar studies.
Blood pressure can be spuriously elevated in apprehen-
sive individuals, the so-called white coat effect [30]. This is
a type of measurement error is an inevitable limitation of
studies such as this where all measurements are done in a
clinical setting in a single sitting. To reduce bias from this
source, only the mean of the last two of three measure-
ments was analysed.
Antihypertensive use was based in part on self-reported
medication data and, as such, potentially prone to recall
and other reporting biases. There is however evidence in
the literature that self-reports of CVD medication are ac-
curate [31, 32].
Conclusion
There were high levels of uncontrolled hypertension in
both countries, although more so in the Russian than the
Norwegian study population. Antihypertensive monother-
apies were commonly used in both countries counter to
European treatment guidelines, especially in Norway. Our
findings suggest considerable scope for promoting the use
of combination therapies for those uncontrolled on a sin-
gle drug. The relatively high proportions of patients not
controlled despite being on multiple antihypertensive
drugs, furthermore, points to the need to invite patients
for individual review of their treatment and any barriers
they face adhering to treatment. Further studies should
thus include non-adherence in those with uncontrolled
hypertension as well as a more in-depth study of patients
with aTRH.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12872-020-01407-2.
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Additional file 1: Figure S1. Sample selection flow diagram.
Hypertension was defined as self-reported antihypertensive use or high
blood pressure (140+/90+ mmHg). Table S1. Age- and gender-adjusted
odds ratios (AOR) of uncontrolled versus controlled hypertension and the
association with antihypertensive drug class combinations by study:
Know Your Heart (KYH, Russia) and Tromsø 7 (T7, Norway).
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